US equities
|
MU
$1,067.96
▼-0.64%
NVDA
$236.40
▲+1.05%
INTC
$115.69
▼-3.05%
META
$728.63
▲+0.08%
AMD
$628.84
▼-0.80%
PTC
$195.89
▲+36.01%
SPCX
$159.29
▲+0.21%
TSLA
$368.26
▼-0.63%
MU
$1,067.96
▼-0.64%
NVDA
$236.40
▲+1.05%
INTC
$115.69
▼-3.05%
META
$728.63
▲+0.08%
AMD
$628.84
▼-0.80%
PTC
$195.89
▲+36.01%
SPCX
$159.29
▲+0.21%
TSLA
$368.26
▼-0.63%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Ocugen, Inc. - Common Stock
(NQ:
OCGN
)
1.020
UNCHANGED
Delayed Quote
Updated: 9:30 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocugen, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
36
37
Next >
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
April 13, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
April 13, 2024
WHY: NEW YORK, NY - (NewMediaWire) - April 13, 2024 - Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen,...
Via
TheNewswire.com
Topics
Lawsuit
ROSEN, A LONGSTANDING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
April 12, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
OCGN Stock Alert: Why Is Ocugen Up 20% Today?
↗
April 05, 2024
With Ocugen receiving a green light to move ahead with a key retinal therapeutic, OCGN stock jumped on the positive implications.
Via
InvestorPlace
Why Ocugen Shares Are Popping Off
↗
April 03, 2024
Ocugen shares are trading higher by 14% during Wednesday's session. The company provided an update on its business activities and financial status for 2023.
Via
Benzinga
ROSEN, A LONGSTANDING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
April 12, 2024
WHY: NEW YORK, NY - (NewMediaWire) - April 12, 2024 - Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Ocugen,...
Via
TheNewswire.com
Topics
Lawsuit
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
April 12, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
April 12, 2024
From
Ocugen
Via
GlobeNewswire
OCUGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm
April 11, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
April 11, 2024
From
Schall Law
Via
GlobeNewswire
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Ocugen, Inc. (OCGN)
April 11, 2024
From
Robbins LLP
Via
GlobeNewswire
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc. Incorporated Investors – OCGN
April 11, 2024
From
Rosen Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
April 10, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
April 10, 2024
From
Ocugen
Via
GlobeNewswire
OCUGEN LOSS ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Inquire About Securities Class Action Investigation – OCGN
April 09, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Why Is Auddia (AUUD) Stock Up 192% Today?
↗
April 08, 2024
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.
Via
InvestorPlace
Topics
Artificial Intelligence
Why Ocugen Shares Are Trading Higher
↗
April 08, 2024
Ocugen shares are trading higher by 7.7% during Monday's session. The company announced U.S. FDA clearance of the IND amendment to initiate a Phase 3 clinical trial of OCU400.
Via
Benzinga
Why Is Ocugen (OCGN) Stock Up 7% Today?
↗
April 08, 2024
Ocugen is returning to its eye treatment roots after a brief life as a Covid-19 vaccine meme stock in 2021 delivered OCGN stock no results.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
April 08, 2024
Via
Benzinga
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
April 08, 2024
From
Ocugen
Via
GlobeNewswire
Why Ocugen Stock Is Climbing Today
↗
April 05, 2024
Ocugen shares are trading higher Friday after the company announced it has received approval to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of its Phase 1/2 study. Ocugen...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
April 05, 2024
Via
Benzinga
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
April 05, 2024
From
Ocugen
Via
GlobeNewswire
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
↗
April 03, 2024
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.
Via
Benzinga
Topics
Stocks
OCUGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Ocugen, Inc. on Behalf of Ocugen Stockholders and Encourages Investors to Contact the Firm
April 02, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Ocugen (OCGN) Q4 2023 Earnings Call Transcript
↗
April 02, 2024
OCGN earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
OCGN Stock Falls Ocugen Must Restate Its Financials
↗
April 02, 2024
After an impressive rally to date, investors appear to be in selling mode with OCGN stock on the news it will need to restate its financials.
Via
InvestorPlace
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
April 02, 2024
Conference Call and Webcast Today at 8:30 a.m. ET
From
Ocugen
Via
GlobeNewswire
Earnings Scheduled For April 2, 2024
↗
April 02, 2024
Companies Reporting Before The Bell • Ocugen (NASDAQ:OCGN) is estimated to report earnings for its fourth quarter.
Via
Benzinga
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
April 01, 2024
From
Ocugen
Via
GlobeNewswire
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
36
37
Next >
